{"title":"Discovery of Novel Peptidomimetics for Brain-Derived Neurotrophic Factor using Phage Display Technology","authors":"Fatemeh Nafian, M. Rasaee, S. Yazdani, Z. Soheili","doi":"10.22034/IJPS.2018.37554","DOIUrl":null,"url":null,"abstract":"Brain-Derived Neurotrophic Factor (BDNF) is a neuroprotectant candidate for neurodegenerative diseases. However, there are several clinical concerns about its therapeutic applications. In the current study, we selected BDNF-mimicking small peptides from phage-displayed peptide library as alternative molecules to the clinical challenges. The peptide library was screened against BDNF receptor (Neurotrophic Tyrosine Kinase Receptor Type 2, NTRK2) and evaluated by ELISA. Polyclonal phage ELISA indicated that target populations were enriched round by round and the panning process was truly effective. The results of monoclonal phage-ELISA showed that all clones had principally bound to NTRK2 but fifteen best clones were sequenced, which twelve of them have SGVYKVAYDWQH (peptide 1) sequence, two pairs were GLHTSATNLYLH (peptide 2), and TVLSHPSTATLI (peptide 3) and one sequence was QQRPYVQDLRLI (peptide 4). Alignment of these peptides and BDNF sequence showed that the resulting peptides conformationally mimicked loop 2 (E40-KVPVSKGQLK-Q51) of BDNF. This region of BDNF is responsible for specific receptor binding and biological activity. According to the similarity of these peptides with BDNF, they could be considered as novel peptidomimetics with therapeutic properties. In addition, modeled peptides were submitted to Protein Model Data Base (peptides 1, 2, 3 and 4 as PMDB ID: PM0081104, PM0081105, PM0081106, PM0081107, respectively).","PeriodicalId":14582,"journal":{"name":"Iranian Journal of Pharmaceutical Sciences","volume":"14 1","pages":"9-20"},"PeriodicalIF":0.0000,"publicationDate":"2018-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22034/IJPS.2018.37554","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 1
Abstract
Brain-Derived Neurotrophic Factor (BDNF) is a neuroprotectant candidate for neurodegenerative diseases. However, there are several clinical concerns about its therapeutic applications. In the current study, we selected BDNF-mimicking small peptides from phage-displayed peptide library as alternative molecules to the clinical challenges. The peptide library was screened against BDNF receptor (Neurotrophic Tyrosine Kinase Receptor Type 2, NTRK2) and evaluated by ELISA. Polyclonal phage ELISA indicated that target populations were enriched round by round and the panning process was truly effective. The results of monoclonal phage-ELISA showed that all clones had principally bound to NTRK2 but fifteen best clones were sequenced, which twelve of them have SGVYKVAYDWQH (peptide 1) sequence, two pairs were GLHTSATNLYLH (peptide 2), and TVLSHPSTATLI (peptide 3) and one sequence was QQRPYVQDLRLI (peptide 4). Alignment of these peptides and BDNF sequence showed that the resulting peptides conformationally mimicked loop 2 (E40-KVPVSKGQLK-Q51) of BDNF. This region of BDNF is responsible for specific receptor binding and biological activity. According to the similarity of these peptides with BDNF, they could be considered as novel peptidomimetics with therapeutic properties. In addition, modeled peptides were submitted to Protein Model Data Base (peptides 1, 2, 3 and 4 as PMDB ID: PM0081104, PM0081105, PM0081106, PM0081107, respectively).
期刊介绍:
Iranian Journal of Pharmaceutical Sciences (IJPS) is an open access, internationally peer-reviewed journal that seeks to publish research articles in different pharmaceutical sciences subdivisions: pharmacology and toxicology, nanotechnology, pharmaceutics, natural products, biotechnology, pharmaceutical chemistry, clinical pharmacy and other pharmacy related topics. Each issue of the journal contents 16 outstanding research articles in area of pharmaceutical sciences plus an editorial written by the IJPS editors on one of the most up to date advances topics in pharmacy. All articles published by IJPS would be permanently accessible online freely without any subscription charges. Authors of the published articles have granted the right to use and disseminate their article to third parties.